Un nuevo medicamento (BU-105) en el tratamiento de la migraña
Abstract
Se informan los resultados obtenidos ron la administración del BC 105 en el tratamiento profiláctico de la cefalea migrañosa. Los mismos fueron valorados romo buenos en 7 de los 10 casos estudiados, con ausencia de efectos secundarios importantes. Se señala que estos resultados lo sitúan como un medicamento preferible al deseril y otros similar. Se revisan las teorías sobre la fisiopatogenia da la migraña, así como algunos de los hechos que las explican. Se destacan las propiedades de este medicamento.Downloads
Downloads
Published
How to Cite
Issue
Section
License
The Cuban Journal of Medicine protects the author's patrimonial rights. However, it is licensed under a Creative Commons Licensehttps://creativecommons.org/licenses/by-nc/4.0/deed.es_ES which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is duly cited. The author always retains his moral rights.
You are free to:
- Share - copy and redistribute the material in any medium or format.
- Adapt - remix, transform and build upon the material
- The license cannot revoke these freedoms as long as you follow the terms of the license.
Under the following terms:
- Attribution - You must give proper credit, provide a link to the license, and indicate if changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is supported by the licensor.
- Non-Commercial Purpose- You may not make use of the material for commercial purposes.
- No Additional Restrictions - You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
